| 14.18 0.05 (0.35%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 18.94 | 1-year : | 21.43 |
| Resists | First : | 16.22 | Second : | 18.35 |
| Pivot price | 13.93  |
|||
| Supports | First : | 12.77 | Second : | 10.63 |
| MAs | MA(5) : | 14  |
MA(20) : | 14.02 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -0.4 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 57.3 |
D(3) : | 52.2 |
| RSI | RSI(14): 48.1 |
|||
| 52-week | High : | 24 | Low : | 12.77 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ANRO ] has closed below upper band by 35.6%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 14.2 - 14.25 | 14.25 - 14.3 |
| Low: | 13.78 - 13.85 | 13.85 - 13.91 |
| Close: | 14.06 - 14.17 | 14.17 - 14.27 |
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor for the treatment of MDD. In addition, the company develops novel pharmacodynamically synergistic combinations and an AI-enabled biomarker platform that combine sources of information on patients brain activity and behavior to identify patients to respond to novel product candidates. Alto Neuroscience, Inc. was incorporated in 2019 and is based in Los Altos, California.
Wed, 24 Apr 2024
Alto Neuroscience (NYSE:ANRO) Trading Up 1.8% - MarketBeat
Tue, 23 Apr 2024
Treatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In Neuropsychiat - Benzinga
Tue, 23 Apr 2024
Alto Neuroscience schizophrenia treatment shows good phase 1 results - Seeking Alpha
Tue, 23 Apr 2024
Alto Neuroscience reports positive Phase 1 results for ALTO-101 - Investing.com South Africa
Tue, 09 Apr 2024
Alto Neuroscience (ANRO): Strong Industry, Solid Earnings Estimate Revisions - Yahoo Finance
Mon, 01 Apr 2024
Alto neuroscience CFO Nicholas Smith purchases shares worth over $100k - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 27 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 13.1 (%) |
| Held by Institutions | 39.1 (%) |
| Shares Short | 2,400 (K) |
| Shares Short P.Month | 1,540 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -34.4 % |
| Return on Equity (ttm) | -68 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.4 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -11.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|